Brief: RhoVac: Positive Results From Clinical Phase I/II Study Published In Journal Of Immunotherapy Of Cancer

Chosa Oncology AB

13/11/2020 08:37

Nov 13 (Reuters) - RhoVac AB  RHOVAC.TE :
    * POSITIVE RESULTS FROM RHOVAC'S CLINICAL PHASE I/II STUDY
PUBLISHED IN JOURNAL OF IMMUNOTHERAPY OF CANCER
    * SCIENTIFICALLY REVIEWED ARTICLE REPORTS THAT TREATMENT
WITH
RHOVAC'S DRUG CANDIDATE RV001 WAS SAFE AND WELL TOLERATED
    * STUDY MET BOTH PRIMARY AND SECONDARY ENDPOINTS,
DEMONSTRATING AN
EXCELLENT SAFETY AND TOLERABILITY PROFILE,
    * SCIENTIFICALLY REVIEWED ARTICLE REPORTS THAT A
LONG-LASTING
IMMUNE RESPONSE COULD BE GENERATED IN VAST MAJORITY OF PATIENTS
    * AS PREVIOUSLY REPORTED, RV001 WAS WELL TOLERATED, AND NO
SERIOUS
TREATMENT-RELATED ADVERSE REACTIONS WERE OBSERVED.
    * MOST PATIENTS DEVELOPED A STRONG CD4 T-CELL RESPONSE THAT
LASTED
FOR AT LEAST TEN MONTHS AFTER LAST INJECTION OF TREATMENT

Source text for Eikon:  ID:nWkrbXmPWc 
Further company coverage:  RHOVAC.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))